Evidence map›Paper›PMID 31455289›Full record

ArticleBMC endocrine disorders2019

Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study.

James B Wetmore, Suying Li, Thanh G N Ton, Yi Peng, Michael K Hansen, Cheryl Neslusan, Ralph Riley, Jiannong Liu, David T Gilbertson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

James B WetmoreChronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA. James.Wetmore@hcmed.org.ORCID http://orcid.org/0000-0003-1380-8597
Suying LiChronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA.
Thanh G N TonPrecision Health Economics, Oakland, California, USA.
Yi PengChronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA.
Michael K HansenJanssen Research & Development, LLC, Spring House, PA, USA.
Cheryl NeslusanJanssen Global Services, LLC, Raritan, NJ, USA.
Ralph RileyJanssen Global Services, LLC, Raritan, NJ, USA.
Jiannong LiuChronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA.
David T GilbertsonChronic Disease Research Group, Hennepin Healthcare Research Institute, 701 Park Avenue, Suite S4.100, Minneapolis, MN, 55415, USA.
Hennepin Healthcare Research Institute · USJanssen (United States) · US

Funding

Janssen Pharmaceuticals n/a
6 · The paper itself

Abstract

backgroundDiabetes-related kidney disease is associated with end-stage renal disease and mortality, but opportunities remain to quantify its association with cardiovascular and non-cardiovascular morbidity outcomes.

methodsWe used the Truven Health MarketScan Commercial Claims and Encounters Database, 2010-2014, which includes specific health services records for employees and their dependents from a selection of large employers, health plans, and government and public organizations. We used administrative claims data to quantify the association between diabetes-related kidney disease and end-stage renal disease, myocardial infarction, congestive heart failure, stroke, and infections. Cox proportional hazard regression models were used to estimate adjusted hazard ratios of developing complications.

resultsAmong 2.2 million patients with diabetes, 7.1% had diabetes-related kidney disease: 13.5%, stage 1-2; 33.8%, stage 3; 13.2% stages 4-5; 39.5%, unknown stage. In multivariable Cox proportional hazard models adjusted for demographic characteristics, baseline comorbid conditions, and total hospital days during the baseline period, hazard ratios for each outcome increased with greater diabetes-related kidney disease severity (stage 1-2 vs. stage 4-5) compared with no diabetes-related kidney disease: myocardial infarction, 1.2 (95% confidence interval 1.1-1.4) and 3.1 (2.9-3.4); congestive heart failure, 1.7 (1.6-1.9) and 5.6 (5.3-5.8); stroke, 1.3 (1.2-1.5) and 2.3 (2.1-2.5); infection, 1.4 (1.3-1.5) and 2.9 (2.8-3.0). Among patients with stage 4-5 disease, 36-month cumulative incidence was nearly 22.8% for congestive heart failure, and 25.8% for infections.

conclusionsDiabetes-related kidney disease appears to be formally diagnosed at a more advanced stage than might be expected, given clinical practice guidelines. Risks of cardiovascular and non-cardiovascular outcomes are high.

Indexed as

AdolescentAdultBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanCardiovascular diseaseDiabetesEnd-stage renal diseaseKidney disease

Identifiers

PMID31455289
PMCPMC6712860
OpenAlexW2970895640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.